MonkeypoxMpox (monkeypox) vaccination recommendations
Recommendations for the use of prepre- and postpost-exposure exposure vaccination during aan monkeypoxmpox incident.
- From:
- UK Health Security Agency
- Published
- 20 May 2022
- Last updated
-
2620AugustNovember20222024 — See all updates
Applies to England
Documents
[Withdrawn] Recommendations for the use of pre and post exposure vaccination during aan monkeypoxmpox incident
Ref: UKHSA gateway number GOV-13161
PDF, 422988 KB, 23 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email publications@phe.gov.ukpublications@ukhsa.gov.uk.
Please tell us what format you need. It will help us if you say what assistive technology you use.
Ref: UKHSA gateway number GOV-13161
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email publications@phe.gov.ukpublications@ukhsa.gov.uk.
Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This document includes information on:
- pre-exposure vaccination for occupational exposure
- post-exposure vaccination
- vaccine prescribing and administration
- consent and record forms
- Imvanex® patient information leaflet
Further monkeypoxmpox guidance is also available, including information on case definitions and contact tracing.
Updates to this page
Last updated
-
Guidance withdrawn.
-
Added version 12, removed appendices 2 to 5.
-
Updated to include the use of intradermal administration for pre and post-exposure use in healthy adults, limiting post-exposure vaccination to children under 5 and immunosuppressed individuals, during periods of limited supply, and further clarification on vaccine eligibility for occupational exposure.
-
Updated guidance, version 10.
-
Version 9: updated background and added a link to classification of contacts (appendix 6), along with advice for vaccination and follow-up.
-
Updated appendix 6 to clarify recommendations for PEP after 14 days since last exposure.
-
Updated guidance, version 7.
-
Updated guidance, version 6.7.
-
Added links to additional monkeypox guidance.
Update history
2024-11-20 10:32
Guidance withdrawn.
2022-08-26 16:31
Added version 12, removed appendices 2 to 5.
2022-08-22 17:53
Updated to include the use of intradermal administration for pre and post-exposure use in healthy adults, limiting post-exposure vaccination to children under 5 and immunosuppressed individuals, during periods of limited supply, and further clarification on vaccine eligibility for occupational exposure.
2022-08-05 16:32
Updated guidance, version 10.
2022-06-17 15:40
Version 9: updated background and added a link to classification of contacts (appendix 6), along with advice for vaccination and follow-up.
2022-06-06 17:41
Updated appendix 6 to clarify recommendations for PEP after 14 days since last exposure.
2022-06-01 19:15
Updated guidance, version 7.
2022-05-27 17:57
Updated guidance, version 6.7.
2022-05-21 15:40
Added links to additional monkeypox guidance.
2022-05-20 17:38
First published.